ATM-dependent spontaneous regression of early Em-myc-induced murine B-cell leukemia depends on natural killer and T cells

Blood

Volumn 121, Issue 13, 2013, Pages 2512-2521

  Ludovic Croxford, J ^a   Tang, Melissa Li Fang ^a   Pan, Meng Fei ^a   Huang, Caleb Weihao ^b   Kamran, Neha ^a   Phua, Cindy Meow Ling ^b   Chng, Wee Joo ^c   Ng, Siok Bian ^c   Raulet, David H ^d   Gasser, Stephan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CD3 ANTIGEN; CD4 ANTIGEN; CD81 ANTIGEN; CELL ADHESION MOLECULE; CHECKPOINT KINASE 1; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; DNAM 1 PROTEIN; HISTONE H2AX; LIGAND; MYC PROTEIN; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; IMMUNOGLOBULIN MU CHAIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE RESPONSE; IMMUNE EVASION; LEUKEMIA REMISSION; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CELL TRANSFORMATION; ENHANCER REGION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR REGRESSION;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA-BINDING PROTEINS; ENHANCER ELEMENTS, GENETIC; GENES, MYC; IMMUNOGLOBULIN MU-CHAINS; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; MICE; MICE, SCID; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASM REGRESSION, SPONTANEOUS; PROTEIN-SERINE-THREONINE KINASES; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84878416534     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-449025     Document Type: Article

References (54)

1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990.
2. Adams JM, Gerondakis S, Webb E, et al. Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc Natl Acad Sci USA. 1983;80(7):1982-1986.
3. Langdon WY, Harris AW, Cory S, et al. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986;47(1): 11-18.
4. Sidman CL, Denial TM, Marshall JD, et al. Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice. Cancer Res. 1993;53(7): 1665-1669.
5. Harris AW, Pinkert CA, Crawford M, et al. The E mu-myc transgenic mouse. A model for highincidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
6. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA. 2006;103(5):1446-1451.
7. Ray S, Atkuri KR, Deb-Basu D, et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 2006;66(13):6598-6605.
8. Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol Cell. 2002;9(5):1031-1044.
9. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA. 2008;105(5):1686-1691.
10. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26(56): 7773-7779.
11. Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-870.
12. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434(7035):907-913.
13. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190.
14. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15):3503-3511.
15. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
16. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol. 2009;9(8):568-580.
17. Guerra N, Tan YX, Joncker NT, et al. NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571-580.
18. Nepal RM, Zaheen A, Basit W, et al. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice. Oncogene. 2008; 27(34):4752-4756.
19. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567.
20. Iguchi-Manaka A, Kai H, Yamashita Y, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med. 2008;205(13): 2959-2964.
21. Corcoran LM, Tawfilis S, Barlow LJ. Generation of B lymphoma cell lines from knockout mice by transformation in vivo with an Emu-myc transgene. J Immunol Methods. 1999;228(1-2): 131-138.
22. Yukawa K, Kikutani H, Inomoto T, et al. Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer (E mu)- myc transgenic mice. J Exp Med. 1989;170(3): 711-726.
23. Lovec H, Grzeschiczek A, Kowalski MB, et al. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13(15):3487-3495.
24. Bodrug SE, Warner BJ, Bath ML, et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13(9):2124-2130.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
26. Ma A, Fisher P, Dildrop R, et al. Surface IgM mediated regulation of RAG gene expression in E mu-N-myc B cell lines. EMBO J. 1992;11(7): 2727-2734.
27. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148.
28. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244.
29. Shibuya K, Lanier LL, Phillips JH, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity. 1999;11(5): 615-623.
30. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol. 2006; 16(5):344-347.
31. Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478(7370):515-518.
32. Reimann M, Loddenkemper C, Rudolph C, et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood. 2007;110(8): 2996-3004.
33. Nepal RM, Tong L, Kolaj B, et al. Msh2- dependent DNA repair mitigates a unique susceptibility of B cell progenitors to c-Mycinduced lymphomas. Proc Natl Acad Sci USA. 2009;106(44):18698-18703.
34. Dardalhon V, Schubart AS, Reddy J, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005;175(3):1558-1565.
35. Bottino C, Castriconi R, Moretta L, et al. Cellular ligands of activating NK receptors. Trends Immunol. 2005;26(4):221-226.
36. Shibuya A, Campbell D, Hannum C, et al. DNAM- 1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-581.
37. Bryceson YT, March ME, Ljunggren H, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159-166.
38. Shibuya K, Shirakawa J, Kameyama T, et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 2003;198(12):1829-1839.
39. Seder RA, Gazzinelli R, Sher A, et al. Interleukin 12 acts directly on CD41 T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA. 1993;90(21): 10188-10192.
40. Wall L, Burke F, Barton C, et al. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res. 2003;9(7): 2487-2496.
41. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109(12):5346-5354.
42. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(1) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637-650.
43. Xie Y, Akpinarli A, Maris C, et al. Naive tumorspecific CD4(1) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207(3):651-667.
44. Rakhra K, Bachireddy P, Zabuawala T, et al. CD4 (1) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18(5):485-498.
45. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005;6(8):635-645.
46. Carlsten M, Norell H, Bryceson YT, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009;183(8):4921-4930.
47. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317(5836):337.
48. Wang E, Selleri S, Sabatino M, et al. Spontaneous and treatment-induced cancer rejection in humans. Expert Opin Biol Ther. 2008; 8(3):337-349.
49. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1-27.
50. Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations. Am J Hematol. 1989;31(2):138-141.
51. Papac RJ. Spontaneous regression of cancer: Possible mechanisms. In Vivo. 1998;12(6): 571-578.
52. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146.
53. Gilfillan S, Chan CJ, Cella M, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;205(13):2965-2973.
54. Sengupta N, MacFie TS, MacDonald TT, et al. Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract. 2010;206(1):1-8.